NAION rare dangerous eye disorder

[HB_22]

It's official.

June 6 (Reuters) - The European Medicines Agency's safety committee has concluded that the use of Novo Nordisk's (NOVOb.CO), opens new tab popular weight-loss drug Wegovy and its treatments for type 2 diabetes may cause rare occurrences of a potentially dangerous eye condition.

Called non-arteritic anterior ischemic optic neuropathy (NAION), the condition may affect up to 1 in 10,000 people taking semaglutide, the active ingredient in Wegovy and Novo's diabetes drugs Ozempic and Rybelsus, the regulator said on Friday.

https://www.reuters.com/business/healthcare-pharmaceuticals/ozempic-wegovy-may-cause-rare-eye-condition-ema-says-2025-06-06/

Seems to me like this is more of a problem for diabetics, as these findings are from studies with diabetics and semaglutide.

 

[Vicki]

Has this been seen at all in tirzepatide or older glp1 like liraglutide? Its interesting that it seems to only be reported with sema

 

[Ghoul]

This has to do with blood glucose control improving too quickly for some diabetics.

Nothing to do with non-diabetics, and even then, it's very rare.

 

[The_Thinking_Elf]

I assume that they will now start clamping down a bit more on private prescriptions in the UK because of this issue (even though I agree this is a tiny risk).

Have been seeing a shift over the last 6 months or so from "very few checks beyond a few pictures" to "videos and F2F consultations" for an initial private prescription.